AI Edition - It's AI Time - 334 [15-03-2025]

AI Edition - It's AI Time - 334

Manus AI can be your personal travel planner – This chatbot crafts a 3-day Hanoi trip under 15M VND (about $590), using human-like skills! It thinks (plans, tracks, recovers from errors), searches across multiple engines, and browses websites to extract info, book, and suggest activities. Whether your budget is modest or big, it ensures you have the best trip possible. You can view its process here.

Anthropic is doing well this year with strong revenue, thanks to its role in powering the popular new app, Manus. Their business is growing fast as a result.

Despite having 21 billion parameters, which is smaller than many other models, Reka Flash 3 performs exceptionally well, especially for tasks like general chat, coding, and following instructions. It is competitive with larger proprietary models like OpenAI’s o1-mini, making it a great choice for low-latency applications.

Sam Altman shared that OpenAI has trained a new model that's really good at creative writing. He even said, "It's the first time I’ve been truly impressed by something written by AI."

Nous Research, a New York-based AI collective, launched an Inference API for easier access to its models. Unlike big tech companies, they focus on unrestricted, personalized, and transparent AI, giving users more control. Join their waitlist here.

Alibaba just launched a new AI model called R1-Omni. It can read emotions by analyzing a person’s facial expressions in videos, adding emotional intelligence to computer vision. And the best part? You can download it for free on Hugging Face.

Researchers at the University of Science and Technology of China (USTC) introduced the Zuchongzhi-3, a superconducting quantum computing prototype. This quantum chip is 1 quadrillion times faster than the world’s fastest supercomputers and 1 million times faster than Google’s Sycamore processor.

Daily AI Fundraising: Insilico Medicine raised $110 million in Series E funding, bringing its valuation to over $1 billion. Led by Value Partners Group, the funds will support AI-designed drugs, including a promising IPF candidate.